FIND’s Post

“While breaking down barriers and improving health equity, Infectious Disease Connect's academic, tele-ID service has been proven to be a win-win solution for both patients and providers.” 🤝👏 #ICYMI, Infectious Disease Connect’s latest white paper showcases the positive impact of #telemedicine in addressing disparities in infectious disease care, focusing on a reduction in ID patient consult average length of stay. Interested in learning more? Download the white paper here: https://lnkd.in/etv-YHYB

Today, the U.S. Department of Health and Human Services (HHS) announced five winners in the #LymeXDiagnosticsPrize, a competition to accelerate the development of Lyme disease diagnostics. This winner announcement is a monumental step forward for a new #Lyme diagnostic — as well as for the new HHS National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People. Luminary Labs is proud to design and produce this multiphase #LymeX competition. Vectors — biting insects and arachnids like mosquitoes, ticks, fleas, and lice — can spread pathogens that are major causes of death and illness worldwide. Diseases spread by vectors include #Lymedisease, #Zika virus, West Nile Virus, #dengue, #malaria, plague, Rocky Mountain Spotted Fever, and Alpha-gal Syndrome. Co-led by the Office of the Assistant Secretary for Health (OASH) and Centers for Disease Control and Prevention, the national strategy identifies and describes federal priorities to detect, prevent, respond to, and control diseases and conditions caused by vectors in the United States. Meet the winners and learn more about this important work: https://lnkd.in/dhbcDpnK

Active surveillance like this project fills in some of the significant knowledge gaps associated with vector-bourne diseases like JEV.

In the wake of COVID-19, the landscape for infectious disease research has been dominated by innovation across treatment modalities. This roundtable summary in partnership with Cerba Research covers panelist discussion about the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials. Get the PDF now: https://ow.ly/XIjl50S7gjm. #InfectiousDiseaseResearch #ClinicalTrials #VaccineDevelopment #EpidemiologicSurveillance #InnovationInHealthcare #HealthcareTechnology #PublicHealth

In the wake of COVID-19, the landscape for infectious disease research has been dominated by innovation across treatment modalities. This roundtable summary in partnership with Cerba Research covers panelist discussion about the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials. Get the PDF now: https://ow.ly/CMVB50S7c3b. #InfectiousDiseaseResearch #ClinicalTrials #VaccineDevelopment #EpidemiologicSurveillance #InnovationInHealthcare #HealthcareTechnology #PublicHealth

In the wake of COVID-19, the landscape for infectious disease research has been dominated by innovation across treatment modalities. This roundtable summary in partnership with Cerba Research covers panelist discussion about the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials. Get the PDF now: https://ow.ly/Z8Ku50S7gyL. #InfectiousDiseaseResearch #ClinicalTrials #VaccineDevelopment #EpidemiologicSurveillance #InnovationInHealthcare #HealthcareTechnology #PublicHealth

In the wake of COVID-19, the landscape for infectious disease research has been dominated by innovation across treatment modalities. This roundtable summary in partnership with Cerba Research covers panelist discussion about the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials. Get the PDF now: https://ow.ly/LhEz50S7gAC. #InfectiousDiseaseResearch #ClinicalTrials #VaccineDevelopment #EpidemiologicSurveillance #InnovationInHealthcare #HealthcareTechnology #PublicHealth

New global initiative: Ecraid's partners with Duke Clinical Research Institute and the Advance-ID Network to address the pressing issue of antibacterial resistance in the world. Stay tuned for more news on this. #AntibioticResistance #GlobalHealth #Healthcare #Partnership #AntimicrobialResistance

The World Health Organization has launched new guidance for conducting comprehensive reviews of national #tuberculosis (#TB) programs! 🌟🌍 This strategic move aims to strengthen TB prevention and care by identifying gaps, enhancing effectiveness, and ensuring that every person in need has access to quality services. With TB remaining one of the world's deadliest infectious diseases, this guidance marks a crucial step forward in our global commitment to #EndTB. Let's unite in this vital effort to save lives and build a healthier future for all. 💪 #GlobalHealth https://bit.ly/3TT2SAP

Very proud to have contributed to this, the first textbook (open access) on rapid research response to disease outbreaks, including preparing for and implementing emergency research. Chapter 7: Research, Sample, and Data Sharing During Outbreaks, Pandemics, and Beyond. https://lnkd.in/g64DnRsg TDR